If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDerwent London Regulatory News (DLN)

Share Price Information for Derwent London (DLN)

Share Price is delayed by 15 minutes
Get Live Data
1,975.00    29.00 (1.49%)
Bid:
1,974.00
Ask:
1,977.00
Spread: 3.00 (0.152%)
Market Cap: £2.20b
DLN Live PriceLast checked at - London Stock Exchange

Intraday Derwent London Share Chart

Directorate change

22 Jan 2026 09:00

RNS Number : 9492P
Derwent London PLC
22 January 2026
 

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

Derwent London plc ("Derwent London" / "the Group")

PAUL WILLIAMS, CHIEF EXECUTIVE, TO RETIRE

Derwent London today announces that Paul Williams has informed the Board of his intention to retire as Chief Executive and Director of the Company.

Paul will remain in his role until his successor is in place at which point he will step down from the Board.

Paul's career at Derwent began shortly after the Company was founded in 1984. He was appointed as an Executive Director in 1998, with responsibility for leasing, asset management and development, and subsequently became Chief Executive in 2019.

A thorough process to appoint a successor, led by the Chairman Mark Breuer, will commence immediately.

Mark Breuer, Chairman, commented: 

"I would like to thank Paul for his dedication and commitment over the last 38 years. During his distinguished career, including his tenure as Chief Executive, he has made an outstanding contribution to Derwent London. With its market leading position, ongoing commitment to capital recycling and significant development pipeline, Derwent London is well placed to create significant value for shareholders."

Paul Williams, Chief Executive, said:

"It has been a huge privilege to have been part of the Derwent story and to have had the opportunity to lead the business over the last six years. I am very proud of what we have achieved, positioning the business with world class assets in prime locations across London, attracting sustained and strong occupational demand. I would like to thank my fellow directors and all the team for their continued hard work and support. I remain fully focused on driving the performance of the business until my successor is in place."

Information equivalent to that required under section 430(2B) of the UK Companies Act 2006 will be made available on the Company's website at the time Paul Williams steps down from the Board and in the Company's 2025 Directors' Remuneration Report.

For further information, please contact:

Derwent London

Tel: +44 (0)20 3478 4217 (Robert Duncan)

Mark Breuer, Chairman

David Lawler, Company Secretary

Robert Duncan, Head of Investor Relations

Brunswick Group

Tel: +44 (0)20 7404 5959

 

 

Simon Sporborg

Nina Coad

Notes to editors

Derwent London plc

Derwent London plc owns a commercial real estate portfolio predominantly in central London valued at £5.2 billion as at 30 June 2025, making it the largest London office-focused real estate investment trust (REIT).

Our experienced team has a long track record of creating value throughout the property cycle by regenerating our buildings via redevelopment or refurbishment, effective asset management and capital recycling. We typically acquire central London properties off-market with low capital values and modest rents in improving locations, most of which are either in the West End or City Borders. We capitalise on the unique qualities of each of our properties - taking a fresh approach to the regeneration of every building with a focus on anticipating tenant requirements and an emphasis on design. Reflecting and supporting our long-term success, the business has a strong balance sheet with modest leverage, a robust income stream and flexible financing.

We are frequently recognised in industry awards for the quality, design and innovation of our projects. Landmark buildings in our 5.3 million sq ft portfolio include 25 Baker Street W1, 1 Soho Place W1, 80 Charlotte Street W1, Brunel Building W2, White Collar Factory EC1, Angel Building EC1 and Tea Building E1.

As part of our commitment to lead the industry in mitigating climate change, Derwent London has committed to becoming a net zero carbon business by 2030, publishing its pathway to achieving this goal in 2020. Our science-based carbon targets have been validated by the Science Based Targets initiative (SBTi). In 2013, we launched a voluntary Community Fund which to date has supported 180 community projects in central London.

The Company is a public limited company, which is listed on the London Stock Exchange and incorporated and domiciled in the UK. The address of its registered office is 25 Savile Row, London, W1S 2ER.

For further information see www.derwentlondon.com or follow us on LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGIGDBIBDDGLD
Date   Source Headline
2nd May 20193:00 pmRNSAdjustment to Conversion Price
2nd May 201912:03 pmRNSHolding(s) in Company
30th Apr 20194:30 pmRNSTotal Voting Rights
30th Apr 20194:00 pmRNSDirector/PDMR Shareholding
30th Apr 20197:00 amRNSFIRST OFFICE PRE-LET AT SOHO PLACE W1
25th Apr 20194:04 pmRNSHolding(s) in Company
23rd Apr 20199:00 amRNSBondholders' meeting
15th Apr 20191:00 pmRNSAnnual Report & Accounts 2018 and Notice of AGM
5th Apr 20194:30 pmRNSDirector/PDMR Shareholding
29th Mar 20193:00 pmRNSDirector Declaration
29th Mar 201911:00 amRNSTotal Voting Rights
28th Mar 20197:00 amRNSBrunel Building Office Space Fully Pre-Let
21st Mar 201911:00 amRNSDirector/PDMR Shareholding
20th Mar 20191:30 pmRNSBlock listing Interim Review
15th Mar 20193:00 pmRNSHolding(s) in Company
13th Mar 201910:30 amRNSDirector/PDMR Shareholding
12th Mar 201910:00 amRNSDirector/PDMR Shareholding
5th Mar 201910:30 amRNSAdditional Listing
28th Feb 20195:00 pmRNSTotal Voting Rights
27th Feb 20199:30 amRNSHolding(s) in Company
26th Feb 20195:00 pmRNSDividend Declaration
26th Feb 20197:00 amRNSRESULTS FOR THE YEAR ENDED 31 DECEMBER 2018
18th Feb 20199:00 amRNSHolding(s) in Company
31st Jan 20194:30 pmRNSTotal Voting Rights
28th Dec 20183:00 pmRNSTotal Voting Rights
13th Dec 20185:00 pmRNSHolding(s) in Company
30th Nov 20181:00 pmRNSTotal Voting Rights
30th Nov 201810:00 amRNSInvestor and Analyst Presentation and Tour
23rd Nov 20187:00 amRNSDirectorate Change
22nd Nov 20187:00 amRNS£250 Million US Private Placement
8th Nov 20187:00 amRNSQ3 2018 Business Update
7th Nov 20183:00 pmRNSHolding(s) in Company
31st Oct 20183:00 pmRNSTotal Voting Rights
17th Oct 201811:00 amRNSAdditional Listing
8th Oct 20189:43 amRNSChange of Credit Rating Agency
4th Oct 20184:00 pmRNSHolding(s) in Company
28th Sep 201811:00 amRNSTotal Voting Rights
20th Sep 20183:00 pmRNSBlock listing Interim Review
12th Sep 20185:30 pmRNSDirector/PDMR Shareholding
31st Aug 20181:00 pmRNSTotal Voting Rights
30th Aug 201811:00 amRNSAdditional Listing
28th Aug 20184:00 pmRNSDirector/PDMR Shareholding
9th Aug 20187:00 amRNSDirectorate Change
9th Aug 20187:00 amRNSHalf-year Results
31st Jul 201811:00 amRNSTotal Voting Rights
30th Jul 201810:00 amRNSHolding(s) in Company
4th Jul 201810:00 amRNSAdditional Listing
2nd Jul 201812:00 pmRNSHolding(s) in Company
29th Jun 20185:00 pmRNSDirector/PDMR Shareholding
29th Jun 20184:30 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.